Evidence map›Paper›PMID 35352939›Full record

ArticleMicrobiology spectrum2022

Clinical Performance of Nanopore Targeted Sequencing for Diagnosing Infectious Diseases.

Yu Fu, Qingsong Chen, Mengyuan Xiong, Jin Zhao, Shucheng Shen, Liangjun Chen, Yunbao Pan, Zhiqiang Li, Yirong Li

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Assessing Nanopore Targeted Sequencing for the Diagnosis of Pulmonary Infections: A Comparative Multidisease Approach.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  6. Review
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yu Fu *Department of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Qingsong Chen *Department of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Mengyuan XiongDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Jin ZhaoDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Shucheng ShenDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Liangjun ChenDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Yunbao PanDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Zhiqiang LiDepartment of Neurosurgery, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.
Yirong LiDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan Universitygrid.49470.3egrid.413247.7, Wuhan, People's Republic of China.ORCID 0000-0002-5619-1614
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gold standard for confirming bacterial infections is culture-positive, which has a long sample-to-result turnaround time and poor sensitivity for unculturable and fastidious pathogens; therefore, it is hard to guide early, targeted antimicrobial therapy and reduce overuse of broad-spectrum antibiotics. Nanopore targeted sequencing (NTS) is reported to be advantageous in detection speed and range over culture in prior published reports. However, investigation of the clinical performance of NTS is deficient at present. Thus, we assessed the feasibility of NTS for the first time with cohort and systematic comparisons with traditional culture assays and PCR followed by Sanger sequencing. This retrospective study was performed on 472 samples, including 6 specimen types from 436 patients, to evaluate the clinical performance of NTS designed for identifying the microbial composition of various infections. Of these samples, 86.7% were found to be NTS positive, which was significantly higher than culture-positive (26.7%). A total of 425 significant human opportunistic bacteria and fungi detected by NTS were selected to go through validation with PCR followed by Sanger sequencing. The average accuracy rate was 85.2% (maximum 100% created by Cryptococcus neoformans, the last one 66.7% provided by both Staphylococcus haemolyticus and Moraxella osloensis, minimum 0% produced by Burkholderia cepacia). The accuracy rate also varied with sample type; the highest accuracy rate was found in pleural and ascites fluid (95.8%) followed by bronchoalveolar lavage fluid (88.7%), urine (86.8%), and wound secretions (85.0%), while the lowest was present in cerebrospinal fluid (58.8%). NTS had a diagnostic sensitivity of 94.5% and specificity of 31.8%. The positive and negative predictive values of NTS were 79.9% and 66.7%, respectively. For diagnosis of infectious diseases, the sensitivity was greatly increased by 56.7% in NTS compared with culture (94.5% vs 37.8%). Therefore, NTS can accurately detect the causative pathogens in infectious samples, particularly in pleural and ascites fluid, bronchoalveolar lavage fluid, urine, and wound secretions, with a short turnaround time of 8-14 h, and might innovatively contribute to personalizing antibiotic treatments for individuals with standardized protocols in clinical practices.

Indexed as

Communicable DiseasesNanoporesAnti-Bacterial AgentsAscitesHumansRetrospective StudiesSensitivity and SpecificityAnti-Bacterial Agentsclinical performanceinfectious diseasesnanopore targeted sequencingpolymerase chain reactionsanger sequencingsensitivity

Identifiers

PMID35352939
PMCPMC9045153
OpenAlexW4220973539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.